MindMed Successfully Completes Phase 1 Clinical Trial of 18-MC
Ryan Allway January 4th, 2022 Psychedelics – Last subject completed study in late 2021 with topline results expected in early 2022 – – Results to inform design of Phase 2a study in individuals undergoing supervised opioid withdrawal – NEW YORK, Jan. 4, 2022 /CNW/ — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED),... Read more
( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )